Browsing Tag
Earlybird Venture Capital
2 posts
Axon Therapies bags $32m to push heart failure trials—can this MedTech deliver where drugs failed?
Axon Therapies raises $32M to advance implant-free heart failure therapy. Learn how its splanchnic ablation trials could reshape cardiology.
Axon Therapies just landed $32mn and a new CEO—can an implant-free heart failure therapy really change the game?
Find out how Axon Therapies’ $32M Series A and new CEO could speed implant-free heart failure trials and European expansion—see what it means for patients.